DexCom earnings beat by $0.03, revenue topped estimates
John Sharkey, Vice President of Business Development at GeoVax Labs, Inc. (NASDAQ:GOVX), has acquired 6,000 shares of the company's common stock, according to a recent SEC filing. The transaction, which took place on April 10, 2025, was valued at approximately $5,940, with each share purchased at a price of $0.99. Following this acquisition, Sharkey holds a total of 6,191 shares in the company. While GeoVax maintains a strong balance sheet with more cash than debt, InvestingPro data reveals 12 additional key insights about the company's financial health and growth prospects, available in the comprehensive Pro Research Report.
In other recent news, GeoVax Labs Inc. reported its financial results for the full year 2024, highlighting a net loss of $25 million, or $4.82 per share, on revenues of $4 million. The revenue primarily came from its BARDA contract, which has been a significant source of income for the company. The company also noted a 14% increase in research and development expenses, amounting to $23.7 million, reflecting its investment in advancing its vaccine pipeline. GeoVax's cash balance stood at $5.5 million as of December 31, 2024.
The company is focusing on strategic initiatives, including clinical trials for its COVID-19 vaccine CM04S1 and its MPOX vaccine, which are expected to start in late 2024 or early 2025. GeoVax continues to explore strategic partnerships and funding strategies to support its development programs. The company's efforts to secure funding are crucial as it navigates financial sustainability challenges amid ongoing net losses. Recent discussions with BARDA and other stakeholders emphasize the importance of the company's vaccine development efforts in addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.